

## Recombinant Vesicular Stomatitis Virus pseudotyped Sudan glycoprotein

**Catalog #:** 1002-001

**Lot #:** 1811004

**Description:** Recombinant Vesicular Stomatitis Virus pseudotyped Sudan glycoprotein (rVSV pseudotyped SUDV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein of Sudan virus. Since the infectivity of rVSV pseudotyped SUDV GP is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.


**Storage:** -80°C

**Size:** 40 µL @ 8.55E+07 RLU/mL is supplied in Advanced DMEM supplemented with 1% Fetal Bovine Serum, L-glutamine and Penicillin/Streptomycin, sufficient for one 96-well assay.

**Relevance:** This rVSV contains Sudan Virus glycoprotein and serves as a tool to enhance filovirus research performed using just biosafety level 2 (BSL-2) containment.

**Related Products:** IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, [www.ibtbioservices.com](http://www.ibtbioservices.com) for more details.

### Neutralization Data:



Anti-SUDV GP mouse mAb 16F6, starting at 3 µg/mL followed by serial dilutions, was incubated with the rVSV pseudotyped with SUDV GP, for one hour prior to adding to Vero cells. Infectivity was determined the next day by assessing luciferase activity. Percent neutralization was calculated based on the control (rVSV pseudotyped with SUDV GP, alone)

### References:

1. Whitt, M.A., Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. *J. Virol. Methods*, 2010. 169(2): p. 365-74.
2. Howell, K.A., et al., Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebola virus. *Cell Reports*, 2017. 19(2): p. 413-424.

**Intended for research use only, not for human, therapeutic, or diagnostic applications.**

*The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.*

**Copyright 2018. Integrated BioTherapeutics, Inc. All rights reserved.**